Form 4: CRISPR Therapeutics CEO Gifts 30,000 Shares

CRISPR Therapeutics CEO Samarth Kulkarni reported gifting 30,000 common shares, reducing his direct beneficial ownership.

Summary

• Samarth Kulkarni, Chief Executive Officer and Director of CRISPR Therapeutics AG, reported a disposition of 30,000 common shares.
• The transaction occurred on December 18, 2025, and was identified as a gift (Transaction Code 'G').
• The shares were disposed of at a price of $0.00 per share, consistent with a gift.
• Following this transaction, Kulkarni directly owns 224,201 common shares.
• Additionally, Kulkarni indirectly owns 85,622 common shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: A neutral event. While it reduces direct ownership, it's a gift rather than a sale, which is generally not seen as a negative signal regarding company performance or outlook. Such transactions are often for personal financial planning.

Positives

• The transaction was a gift rather than a sale for cash, which can sometimes be viewed more favorably by investors as it does not imply a lack of confidence in the company's future.

Negatives

• The transaction resulted in a reduction of 30,000 common shares in the direct beneficial ownership of a key executive.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The direct beneficial ownership of the CEO has decreased by 30,000 shares. However, as this was a gift and not a sale, the impact on shareholder sentiment is likely minimal, not signaling a lack of confidence in the company's prospects.

Key Dates

Recommendation

This Form 4 reports a gift of shares by the CEO, not a sale. While it reduces direct beneficial ownership, it does not signal a lack of confidence in the company's future. Such transactions are often for estate planning or philanthropic purposes and typically have a neutral impact on investment sentiment. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide a strong basis for a change in investment thesis.

Keywords

CRISPR Therapeutics, CRSP, Samarth Kulkarni, Insider Transaction, Form 4, Share Ownership, CEO, Gift